Let's grab coffee

Schedule a meeting or connect with me on LinkedIn to discuss your upcoming study and how PSI can help.

Michael Sommer

Senior Director Business Development
Mobile: +49 (151) 5514 6095

Finally – A truly global CRO suited for small to midsize biotech companies 

We’re a privately held, global CRO that specializes in Phase 2 and 3 clinical trials in select indications, including oncology, hematology, and IBD. We recognize that site relationships are integral to the success of your study, and we have proactively cultivated these relationships for the last 25 years, with more than 2,600 top-performing sites around the world to improve patient enrollment and client trust. That’s one of the reasons 90% of our business is repeat and referral – we know the meaning of trust and reliability.
Read our latest white paper

Learn more with the resources below

Our mission is to be the best CRO in the world as measured by our employees, clients, investigators, and vendors.
Delivering trials is what we do. It’s our expertise – it’s what we’re dedicated to, and it’s what our teams are built for.
Running oncology studies globally. We plan and execute seamless clinical trials with novel study designs.
PSI is one, if not the only, CRO that has been engaged extensively in gene therapy trials by half a dozen biotech sponsors.
As the need for clinical trials in Crohn’s disease and ulcerative colitis grows, CRO collaboration matters more than ever.


For radiopharmaceutical clinical trials, cooperation and coordination on a global scale is a must.
Consistent delivery on dozens of MS trials, expert knowledge of running placebo-controlled MS trials around the world.
Predictable enrollment and deep connections to sites and staff. PSI is an antibiotic powerhouse.
The challenges of rare disease research, a global approach. Predictability in rare disease clinical trials.